Artwork

Conteúdo fornecido por Samir Gondalia, ISPE Boston, Samir Gondalia, and ISPE Boston. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Samir Gondalia, ISPE Boston, Samir Gondalia, and ISPE Boston ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Player FM - Aplicativo de podcast
Fique off-line com o app Player FM !

Episode 8 - David Sullivan on New Modalities, Price, Patients and the Pharma Landscape

29:28
 
Compartilhar
 

Manage episode 337236861 series 3380376
Conteúdo fornecido por Samir Gondalia, ISPE Boston, Samir Gondalia, and ISPE Boston. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Samir Gondalia, ISPE Boston, Samir Gondalia, and ISPE Boston ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.

My guest today is David Sullivan, Sr. Director and Global Lead of Vaccines and Biologics MSAT at Pfizer. He did his Bachelor's in Biotechnology from Worcester Polytechnic Institute and Master's in Engineering Management from Tufts University. Over the years, he's worked in process development, pilot plant, next generation technology, vaccines and biologocs MSAT. I have known Dave for over 15 years and have always been impressed with the width of his knowledge and have never had a boring conversation about anything with him. In this episode, we talk about new modalities, the current changes happening in the pharma industry landscape, the price factor, the patients first philosophy and how that's all going to impact the future of pharma.

Also, check out his book recommendation, "Trillion Dollar Coach" to learn about the leadership lessons from Bill Campbell, a revered executive who was called "Coach" by Steve Jobs, Larry Page, Sergei Brin and Eric Schmidt among others. Here's Dave Sullivan.

  continue reading

27 episódios

Artwork
iconCompartilhar
 
Manage episode 337236861 series 3380376
Conteúdo fornecido por Samir Gondalia, ISPE Boston, Samir Gondalia, and ISPE Boston. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Samir Gondalia, ISPE Boston, Samir Gondalia, and ISPE Boston ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.

My guest today is David Sullivan, Sr. Director and Global Lead of Vaccines and Biologics MSAT at Pfizer. He did his Bachelor's in Biotechnology from Worcester Polytechnic Institute and Master's in Engineering Management from Tufts University. Over the years, he's worked in process development, pilot plant, next generation technology, vaccines and biologocs MSAT. I have known Dave for over 15 years and have always been impressed with the width of his knowledge and have never had a boring conversation about anything with him. In this episode, we talk about new modalities, the current changes happening in the pharma industry landscape, the price factor, the patients first philosophy and how that's all going to impact the future of pharma.

Also, check out his book recommendation, "Trillion Dollar Coach" to learn about the leadership lessons from Bill Campbell, a revered executive who was called "Coach" by Steve Jobs, Larry Page, Sergei Brin and Eric Schmidt among others. Here's Dave Sullivan.

  continue reading

27 episódios

همه قسمت ها

×
 
Loading …

Bem vindo ao Player FM!

O Player FM procura na web por podcasts de alta qualidade para você curtir agora mesmo. É o melhor app de podcast e funciona no Android, iPhone e web. Inscreva-se para sincronizar as assinaturas entre os dispositivos.

 

Guia rápido de referências